Emergent Biosolutions Long Term Debt 2010-2022 | EBS

Emergent Biosolutions long term debt from 2010 to 2022. Long term debt can be defined as the sum of all long term debt fields.
Emergent Biosolutions Annual Long Term Debt
(Millions of US $)
2021 $809
2020 $841
2019 $798
2018 $785
2017 $14
2016 $248
2015 $247
2014 $251
2013 $62
2012 $58
2011 $54
2010 $30
2009 $45
Emergent Biosolutions Quarterly Long Term Debt
(Millions of US $)
2022-06-30 $794
2022-03-31 $802
2021-12-31 $809
2021-09-30 $817
2021-06-30 $825
2021-03-31 $833
2020-12-31 $841
2020-09-30 $849
2020-06-30 $758
2020-03-31 $763
2019-12-31 $798
2019-09-30 $813
2019-06-30 $830
2019-03-31 $732
2018-12-31 $785
2018-09-30 $13
2018-06-30 $13
2018-03-31 $13
2017-12-31 $14
2017-09-30 $249
2017-06-30 $249
2017-03-31 $248
2016-12-31 $248
2016-09-30 $248
2016-06-30 $247
2016-03-31 $247
2015-12-31 $247
2015-09-30 $253
2015-06-30 $253
2015-03-31 $251
2014-12-31 $251
2014-09-30 $251
2014-06-30 $251
2014-03-31 $251
2013-12-31 $62
2013-09-30 $55
2013-06-30 $56
2013-03-31 $57
2012-12-31 $58
2012-09-30 $59
2012-06-30 $58
2012-03-31 $58
2011-12-31 $54
2011-09-30 $49
2011-06-30 $29
2011-03-31 $30
2010-12-31 $30
2010-09-30 $36
2010-06-30 $37
2010-03-31 $44
2009-12-31 $45
2009-09-30 $21
2009-06-30 $21
2009-03-31 $35
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.482B $1.793B
Emergent BioSolutions, Inc. is a global specialty biopharmaceutical company offering specialized products to health care providers and governments to combat emerging public health threats. It also supplies vaccines to domestic and international non-government organizations and governments in/ outside of the U.S. BioThrax is the company's key Biodefense product, used for anthrax disease. The U.S. government is the primary purchaser of the company's Biodefense products. It supplies adjuvanted anthrax vaccine candidate, AV7909, to the U.S. government. It supplies smallpox vaccine ACAM2000, botulism therapeutic BAT, anthrax therapeutics 'raxibacumab & Anthrasil' and 3 other products to governments of different countries. It also retails 3 products Narcan nasal spray, Vaxchora and Vivoti. It provides contract development and manufacturing services to multiple pharma and biotech companies. The company has added key products Narcan nasal spray, ACAM2000, raxibacumab, Vaxchora and Vivoti through several acquisitions.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $160.059B 9.71
GSK (GSK) United Kingdom $81.408B 9.78
Bio-Rad Laboratories (BIO.B) United States $15.412B 34.05
QIAGEN (QGEN) Netherlands $11.018B 18.45
Biohaven Pharmaceutical Holding (BHVN) United States $10.535B 0.00
Ginkgo Bioworks Holdings (DNA) United States $5.561B 0.00
Arcus Biosciences (RCUS) United States $1.821B 35.53
Myovant Sciences (MYOV) United Kingdom $1.600B 0.00
Zymeworks (ZYME) Canada $0.390B 0.00
Enzo Biochem (ENZ) United States $0.120B 0.00
Gelesis Holdings (GLS) United States $0.104B 0.00
SQZ Biotechnologies (SQZ) United States $0.097B 0.00
Ambrx Biopharma (AMAM) United States $0.089B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00